30 Years' follow up of randomised studies of adjuvant CMF in operable breast cancer: Cohort study

British Medical Journal

Volumn 330, Issue 7485, 2005, Pages 217-220

  Bonadonna, Gianni ^a   Moliterni, Angela ^a   Zambetti, Milvia ^a   Daidone, Maria Grazia ^a   Pilotti, Silvana ^a   Gianni, Luca ^a   Valagussa, Pinuccia ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE;

ADULT; AMENORRHEA; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; DRUG EFFICACY; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; ITALY; META ANALYSIS; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; SURVIVAL RATE; SYSTEMATIC REVIEW;

ADULT; AGED; AMENORRHEA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; CYCLOPHOSPHAMIDE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; METHOTREXATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 13244268450     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.38314.622095.8F     Document Type: Article

References (11)

1. Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976;294:405-10.
2. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of randomised trials. Lancet 1998;352:930-42.
3. Pritchard KI. Adjuvant therapy for premenopausal women with breast cancer: is it time for another paradigm shift? J Clin Oncol 2002;20:4611-4.
4. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 1998;16:413-28.
5. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995;332:901-6.
6. Tancini G, Bonadonna G, Valagussa P, Marchini S, Veronesi U. Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. J Clin Oncol 1983;1:2-10.
7. Zambetti M, Bonadonna G, Valagussa P, Daidone MG, Coradini D, Bignami P, et al. Adjuvant CMF for node-negative and estrogen receptor-negative breast cancer. J Natl Cancer Inst Monogr 1992;11:79-85.
8. Jakesz R, Hausmaninger H, Kubista E, Gnant M, Menzel C, Bauernhofer T, et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer-Austrian Breast and Colorectal Cancer Study Group trial 5. J Clin Oncol 2002;20:4621-7.
9. Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex early breast cancer research association study. J Clin Oncol 2002;20:4628-35.
10. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67.
11. Ménard S, Valagussa P, Pilotti S, Gianni L, Biganzoli E, Boracchi P, et al. Response to CMF in lymph-node positive breast cancer according to HER2 overexpression and other tumours biologic variables. J Clin Oncol 2001;19:329-35.